Early prediction of spontaneous Patent Ductus Arteriosus (PDA) closure and PDA-associated outcomes: a prospective cohort investigation

Jonathan L. Slaughter1,2,3, Clifford L. Cua2,4, Jennifer L. Notestine1, Brian K. Rivera1, Laura Marzec1, Erinn M. Hade5, Nathalie L. Maitre1,2, Mark A. Klebanoff1,2,3,6, Megan Ilgenfritz2, Vi T. Le1, Dennis J. Lewandowski1 and Carl H. Backes1,2,4,6*

Abstract

Background: Patent ductus arteriosus (PDA), the most commonly diagnosed cardiovascular condition in preterm infants, is associated with increased mortality and harmful long-term outcomes (chronic lung disease, neurodevelopmental delay). Although pharmacologic and/or interventional treatments to close PDA likely benefit some infants, widespread routine treatment of all preterm infants with PDA may not improve outcomes. Most PDAs close spontaneously by 44-weeks postmenstrual age; treatment is increasingly controversial, varying markedly between institutions and providers. Because treatment detriments may outweigh benefits, especially in infants destined for early, spontaneous PDA closure, the relevant unanswered clinical question is not whether to treat all preterm infants with PDA, but whom to treat (and when). Clinicians cannot currently predict in the first month which infants are at highest risk for persistent PDA, nor which combination of clinical risk factors, echocardiographic measurements, and biomarkers best predict PDA-associated harm.

Methods: Prospective cohort of untreated infants with PDA (n=450) will be used to predict spontaneous ductal closure timing. Clinical measures, serum (brain natriuretic peptide, N-terminal pro-brain natriuretic peptide) and urine (neutrophil gelatinase-associated lipocalin, heart-type fatty acid-binding protein) biomarkers, and echocardiographic variables collected during each of first 4 postnatal weeks will be analyzed to identify those associated with long-term impairment. Myocardial deformation imaging and tissue Doppler imaging, innovative echocardiographic techniques, will facilitate quantitative evaluation of myocardial performance. Aim1 will estimate probability of spontaneous PDA closure and predict timing of ductal closure using echocardiographic, biomarker, and clinical predictors. Aim2 will specify which echocardiographic predictors and biomarkers are associated with mortality and respiratory illness severity at 36-weeks postmenstrual age. Aim3 will identify which echocardiographic predictors and biomarkers are associated with 22 to 26-month neurodevelopmental delay. Models will be validated in a separate cohort of infants (n=225) enrolled subsequent to primary study cohort.

(Continued on next page)
**Discussion:** The current study will make significant contributions to scientific knowledge and effective PDA management. Study results will reduce unnecessary and harmful overtreatment of infants with a high probability of early spontaneous PDA closure and facilitate development of outcomes-focused trials to examine effectiveness of PDA closure in “high-risk” infants most likely to receive benefit.

**Trial registration:** ClinicalTrials.gov NCT03782610. Registered 20 December 2018.

**Keywords:** patent ductus arteriosus, preterm infant, echocardiogram, prospective cohort, prediction modeling

---

**Background**

Patent ductus arteriosus (PDA), the most commonly diagnosed cardiovascular condition in preterm infants, is associated with an eight-fold increase in mortality [1] and multiple, harmful longer-term outcomes including bronchopulmonary dysplasia (BPD) [2–4], intestinal injury [5, 6], brain damage [3, 7–9], cerebral volume loss [10, 11], and congestive heart failure [12, 13]. PDA results in an enduring blood flow in preterm infants between the aorta and the pulmonary artery. The ductus, an essential component of fetal circulation, normally closes shortly after birth in term infants, but remains open (patent) at one-month of age in approximately 70% of <30-weeks gestation preterm infants [12, 14]. PDA-associated symptoms including mesenteric, renal, and cerebral hypoperfusion and pulmonary edema secondary to pulmonary overcirculation develop in 60% of those with persistent PDA [11, 12, 15].

Despite association with worsened outcomes in preterm infants, PDA closure has become increasingly controversial among cardiologists and neonatologists [16], with treatment strategies varying markedly between institutions [17–19] and individual providers [20]. Within the first postnatal month, the majority of neonatal providers still routinely administer nonsteroidal anti-inflammatory drugs, or less commonly acetaminophen, to at least some infants with PDA with the expectation of increased early ductal closure [18, 20]. Because the majority of PDAs in preterm infants close spontaneously by 44-weeks postmenstrual age (PMA) when left untreated, the frequencies of both early medication treatment and surgical or catheter-based closure ligation for persistent PDA have declined over the last decade [17–20].

Given a lack of validated evidence to identify which subset of preterm infants is most likely to benefit from PDA closure [3], the decision to treat PDA remains subjective. Randomized clinical trials [3, 21, 22] and innovative observational studies [18, 23] have not demonstrated net improvement in death, BPD, or neurodevelopmental impairment following routine medical or interventional treatments (surgical ligation, catheter-based closure) of all preterm infants with PDA. However, the effectiveness of more selective PDA treatment closure strategies remains unclear [3, 12, 13].

Nonsteroidal anti-inflammatory drug treatment is linked to nephrotoxicity [24], acute renal failure [25], decreased cerebral and intestinal blood flow [26, 27], intestinal perforation when co-administered with glucocorticoids [28–30], and failure to close the PDA in one-third of infants [31], and costs between $1458 to $1875 per three-dose treatment course [32, 33]. Acetaminophen, a less studied medical option, is associated with neurologic impairment [34, 35]. Surgical ligation via thoracotomy requires exposure to general anesthesia [36, 37]. Vocal-cord paralysis and post-operative hemodynamic instability are also potential risks [38–40]. PDA closure via heart catheterization is potentially less-invasive [41–44]; however, it remains understudied and carries potential complications including arterial injury [41–43]. Since all forms of PDA closure are expensive and associated with adverse effects [38, 41–43, 45, 46], treatment harms may outweigh benefits, especially for the majority of infants destined for early, spontaneous PDA closure.

Still, treatment of some infants with symptomatic PDA is necessary [13]. A subset of preterm infants with persistent PDA continues to display PDA-associated symptoms, including volume overloading of their immature heart and lungs, and worsening respiratory failure [3, 13, 47]. Chronic PDA exposure is associated with congestive heart failure [13, 48, 49] and death [1, 3, 50].

The American Academy of Pediatrics and experts on PDA in preterm infants agree that future outcomes-based randomized clinical trials are needed to determine the effectiveness of selective pharmacological and/or interventional treatments for “high-risk” infants with PDA [3, 12, 13, 51]. The goal is to eventually deliver prompt, personalized PDA treatment to only those infants most likely to benefit [3, 52, 53], thereby reducing the side-effects and costs associated with unnecessary and potentially harmful PDA overtreatment. Unfortunately, no validated prediction models currently exist to permit early identification of those infants with increased probabilities of persistent PDA and PDA-associated harm. As a first step in trial design, the American Academy of Pediatrics has called for the development of comprehensive, echocardiographic- and biomarker-based PDA risk-stratification tools [3].
The objectives of this study are to use a prospective cohort of untreated preterm infants with PDA to accurately predict the timing of spontaneous ductal closure (and conversely, long-term ductal patency) in preterm infants with PDA, and the identification of measurable echocardiographic predictors and biomarkers that are present in the first postnatal month that are associated with mortality, chronic lung disease (CLD), and long-term neurological impairment. These results will ultimately improve neonatal patient care by informing the design of outcomes-focused randomized clinical trials that will examine the effectiveness and timing of PDA closure in those “high-risk” infants most likely to receive benefit [41].

Methods
Research design overview
A number of clinical [54], echocardiographic [4, 55–57], and biomarker [58] variables have known associations with an increased likelihood of either spontaneous PDA closure or PDA-associated morbidity [3]. However, no one has incorporated all reported predictors to develop comprehensive, clinically-focused PDA prediction models. In addition, most prior investigations have been limited by retrospective study designs [4], with echocardiographic surveillance at the clinician’s discretion rather than uniform echocardiogram collection at pre-specified time points. The few prospective studies were limited by exposure measurements at single, early time points [57, 58], short durations of PDA exposure [57], and/or small sample sizes [57, 58]. Historically, most PDA investigations have been conducted at sites favoring early, aggressive PDA treatment, thus preventing an unbiased examination of the relationships between early PDA indicators, spontaneous closure, and outcomes following persistent PDA [4]. The proposed research is innovative because we will prospectively collect sequential echocardiographic measures, serum and urine biomarkers, and important clinical risk factors within a cohort of untreated infants with PDA. We will utilize that data to develop robust models to evaluate their combined ability to predict both spontaneous PDA closure timing, and PDA-associated mortality, respiratory, and long-term neurodevelopmental outcomes. This study uses a prospective cohort and a rigorously designed observational study to answer proposed questions that cannot be answered with a randomized trial, but that are crucial to future PDA trial development.

Study subjects
We will recruit a cohort of <30-weeks gestation preterm infants consecutively enrolled using the following inclusion and exclusion criteria:

Inclusion criteria
1) Infants born between 23-weeks + 0 days (23\textsuperscript{0/7} weeks) and 29\textsuperscript{6/7} weeks of gestation, inclusive
2) Admitted to a study network neonatal intensive care unit (NICU) within 72-hours of birth
3) PDA noted on initial screening echocardiogram at <72 postnatal hours

Exclusion criteria
1) Life-threatening congenital abnormalities including congenital heart disease (other than PDA or small atrial septal defects/patent foramen ovale/muscular ventriculoseptal defects)
2) Infants whose parents have chosen to allow natural death (do not resuscitate order)

Recruitment
Patient screening for eligibility and recruitment
Cohort entry will occur within 72 hours after birth, a time of PDA patency in >95% of infants born at <30-weeks gestational age [54]. The research coordinator will evaluate new admissions; written informed consent will be obtained by a study nurse or co-investigator. Inpatient recruitment for the primary study cohort (n=450) is ongoing (start date 04/01/19; first patient enrolled (04/02/19) with a goal of 2 years. Because prediction models should be validated in a population separate from that in which they were created, inpatient recruitment of a validation cohort (n=225) will begin immediately following primary study cohort enrollment completion. Infants will remain in their respective cohort until follow-up at 22 to 26-months corrected age.

Recruitment sites
Recruitment will take place within the Nationwide Children’s Hospital (NCH) Neonatal Network, one of the largest neonatal intensive care networks in the United States. The NCH Neonatal Network is comprised of 9 hospitals in central Ohio within a 20-minute drive from the NCH research campus, has 268 neonatal beds, and had >420 admissions of infants born at <30-weeks gestation in 2016. Patient demographics, including sex and race/ethnicity, are largely representative of the US population. All sites share clinical-practice guidelines, are staffed by NCH neonatologists, and electronically transmit echocardiographic images to NCH for cardiologist interpretation.

The NCH Neonatal Network is committed to a guideline-driven approach for the care of infants born at <30-weeks gestation [59]. The NCH Neonatal Network designed and implemented a regional consensus guideline for PDA management in 2012 (Slaughter and Backes,
unpublished). Local guidelines mandate that no pharmacologic therapy be used to treat PDA. Interventions to close the PDA (surgical or catheter-based closure) may only be considered after 30 postnatal days as a “last resort” for patients with severe respiratory illness, signs of PDA-associated systemic hypoperfusion (e.g., metabolic acidosis, hypotension, oliguria) and echocardiographic findings of >1.5 mm diameter PDA with increased left cardiac volume load, maximum ductal velocity >2 m/s, or decreased, absent, or reversed end-diastolic abdominal aortic flow. The PDA consensus guidelines and minimally interventional PDA treatment strategies provide a unique opportunity to examine determinants of spontaneous PDA closure among extremely preterm infants who did not receive therapy [20]. Consistent with the switch to guidelines, from 2013-2016 NCH did not perform any surgical PDA ligations or catheter-based closures prior to 30 days postnatal. Since 2012, only 2.6% of infants with PDA have received catheter-based closure, at a median of 38.1 weeks PMA [25th-75th percentiles: 35.4 - 41.4 weeks].

**Data Collection**

**Data entry and monitoring**

Patient demographic, clinical, and sample data will be collected in REDCap (Research Electronic Database Capture), a robust, secure web-based electronic capture tool that allows for real-time data entry with embedded logic and range checks, skip patterns, and missing data alerts to ensure quality control, while minimizing the amount of missing data, and assigned a study ID number [60]. Study data collection forms were designed and implemented with the support of The Ohio State University Center for Clinical and Translational Science, and are stored behind the NCH firewall. The study research coordinator will enter data for each enrolled preterm infant, including clinical, echocardiographic, and biomarker data. Study statisticians will monitor data for completeness and accuracy.

**Clinical signs**

The clinical cardiac examination will be performed consistent with standards outlined by the American Heart Association and American College of Cardiology [61]. To ensure competency and reliability, training in performance and documentation of the cardiac examination will be ensured prior to study commencement by a pediatric cardiologist who will assess inter- and intra-rater reliability. To ensure standardization of the cardiac examination, the pediatric cardiologist will also perform the standardized exam on 10-20% of enrolled infants on the same day as the research nurse exam and provide feedback or correction as needed. All examiners will be masked to echocardiographic and biomarker results.

**Echocardiographic measures**

All echocardiograms will be performed by dedicated and trained research sonographers, including the baseline echocardiogram <72 hours postnatal to determine study eligibility. Consistent with American Heart Association and American College of Cardiology standards [62], the sonographers will have formal training and be certified in pediatric echocardiography. Infants with evidence of a PDA on the baseline echocardiogram will undergo weekly echocardiograms for the first 4 weeks, then biweekly echocardiograms until PDA closure or NICU discharge; an echocardiogram will also be completed at 36-weeks PMA per study protocol. If the baseline echocardiogram shows no evidence of a PDA, infants will continue to be followed prospectively, but without additional echocardiographic studies. If discharged home with an open ductus, infants will follow-up with the pediatric cardiologist (per NCH Neonatal Network standard of care) in the outpatient neonatal-cardiology clinic. All echocardiograms will be performed with a dedicated research ultrasound (CX50; Philips, Amsterdam, The Netherlands). Images will be obtained with the narrowest sector angle to maximize frame rate (goal frame rate >100 frames/s) for optimal image quality [63, 64]. Images will be saved and interpreted by a single pediatric cardiologist who will be masked to patient and clinical data. All recordings will be measured in triplicate and averaged [65]. Consistent with previous work [65–70], images will be analyzed using a dedicated workstation (Tomtec USA, Chicago, IL, USA) [71].

**Risk measurement**

During the first postnatal month, variables collected will allow for adequate control of confounding due to severity of illness, as the independent value of echocardiographic measurements and laboratory biomarkers in predicting important outcomes is established (Aims 2 and 3). Early severity of illness may be both a predictor of the duration of PDA patency and a modifier of the effect of echocardiographic and biomarker-derived PDA measurements on PDA closure (Aim 1).

**Clinical measures**

**Predictor variable data collection within the first postnatal month**

In addition to echocardiograms and laboratory-measured biomarkers, we will collect multiple clinical variables during the perinatal and neonatal period (postnatal days 0-28) to facilitate predicting the time of spontaneous PDA closure (Aim 1), and to control for confounding within our models for mortality and 36-weeks PMA respiratory outcomes (Aim 2) and 22 to 26-months neurodevelopmental outcomes (Aim 3). The following data will be collected: 1) patient demographics; 2) antenatal risk factors; 3) early postnatal measures of illness severity; 4) diagnoses that
present in the first postnatal month (neonatal period); 5) medications; and 6) physiologic measures (Table 1). An overview of the study timeline for each patient is shown in Table 2.

**Clinical markers associated with mortality and neurodevelopmental impairment**

We will include variables routinely collected in preterm infants within the first 12-hours postnatal that comprise the Score for Neonatal Acute Physiology with Perinatal Extension-II (birth weight, 5-minute Apgar score, small [<10th percentile] for gestational age, lowest mean blood pressure, lowest temperature, pO2/FiO2, lowest serum pH, presence of multiple seizures, and low urine output) [72]. This score is a validated predictor [75] of mortality [72, 76], CLD of prematurity [77], and long-term neuro-developmental impairment risk [78, 79]. We will also collect Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network (NRN) Extremely Preterm Outcomes Prediction Tool variables [73]. These variables (e.g., antenatal corticosteroid exposure, female sex, singleton birth, and higher birth weight) are associated with a reduced risk of death and/or neurodevelopmental impairment [74].

**Clinical markers associated with 36-weeks PMA respiratory status**

To determine which early echocardiographic parameters and biomarkers in preterm infants with PDA are independently predictive of respiratory illness severity at 36-weeks PMA (Aim 2), early risk variables from the best clinical prediction model for bronchopulmonary dysplasia (BPD) severity (NICHD NRN Neonatal BPD Outcome Estimator) will be included [80, 81]. Preterm birth-associated CLD in infants at 36-weeks PMA is secondary to BPD, a consequence of preterm lung exposure to the extra-uterine environment. Inflammation from alveolar, systemic, and vascular causes including PDA contribute to disease severity [82–85]. These variables include (but are not limited to): 1) gestational age; 2) birth weight; 3) race/ethnicity; 4) sex; 5) respiratory support (none, nasal cannula, continuous positive airway pressure, conventional ventilation, or high-frequency ventilation); and 6) fraction of inspired oxygen (FiO2). Pulse oximetry continually measures peripheral capillary oxygen saturation throughout NICU hospitalization as standard of care. We will incorporate the daily oxygen saturation index (mean airway pressure × FiO₂ × 100 ÷ peripheral capillary oxygen saturation), which has been validated as a non-invasive alternative to oxygenation index for assessing neonatal hypoxic respiratory failure severity [86].

**Gestational age as a predictor of spontaneous PDA closure**

We retrospectively evaluated (10/2012–7/2017) local infants with echocardiography-diagnosed PDA who were born 23 to 30-weeks gestation and who had at least 2 echocardiograms to allow PDA status verification (open/closed) over time (n=244) (Fig. 1). We evaluated gestational age, birth weight, sex, race, and 5-minute Apgar scores using a multivariable Cox regression. Gestational age was a significant predictor of ductus closure (Hazard ratio: 1.38, 95% confidence interval: 1.20, 1.59). Given our culture of PDA non-treatment in central Ohio relative to most US institutions, the proportion of patients receiving ≥2 echocardiograms was small. Nevertheless, our finding of a higher prevalence of ductal patency in lower gestational age infants, is strikingly similar to findings reported in a larger cohort (HR: 1.28, 95% confidence interval: 1.20, 1.36) [54].

**Effect modification by indomethacin for intraventricular hemorrhage**

A 3-day prophylactic course of indomethacin may be initiated on the date of birth (postnatal days 0–2) to reduce the frequency of intraventricular hemorrhage. Since indomethacin prophylaxis may contribute to PDA

---

### Table 1. Clinical predictor variables

| Patient Demographics | Antenatal Risk Factors | Early Postnatal Illness Severity | Diagnoses in Early Postnatal Period<sup>a</sup> | Medications (by date, dose, route) | Physiologic Measures (date) |
|----------------------|------------------------|---------------------------------|-----------------------------------------------|----------------------------------|-----------------------------|
| Birth GA             | Maternal corticosteroid administration | Apgar scores | Neonatal Acute Physiology (SNAPPE-II) variables [72] | Indomethacin | Daily respiratory support modality |
| Birth weight z-score for GA | Maternal magnesium sulfate administration | Variables from NICHD NRN Extremely Preterm Outcomes Prediction Tool [73, 74] | Neonatal Acute Physiology (SNAPPE-II) variables [72] | Caffeine, Diuretics | Mean arterial blood pressure<sup>b</sup> |
| Sex                  | Pre-eclampsia, Clinical and histological chorioamnionitis | Neonatal Acute Physiology (SNAPPE-II) variables [72] | Neonatal Acute Physiology (SNAPPE-II) variables [72] | Diuretics, Inhaled corticosteroids, Surfactant treatment | Mean arterial blood pressure<sup>b</sup> |
| Race/Ethnicity       | Transported from outside birth | Neonatal Acute Physiology (SNAPPE-II) variables [72] | Neonatal Acute Physiology (SNAPPE-II) variables [72] | Caffeine, Diuretics | Mean arterial blood pressure<sup>b</sup> |
| Hospital             | Singleton or multiple gestation | Neonatal Acute Physiology (SNAPPE-II) variables [72] | Neonatal Acute Physiology (SNAPPE-II) variables [72] | Diuretics, Inhaled corticosteroids | Mean arterial blood pressure<sup>b</sup> |
| Social status (BSMSS) | Birth weight z-score for GA | Neonatal Acute Physiology (SNAPPE-II) variables [72] | Neonatal Acute Physiology (SNAPPE-II) variables [72] | Indomethacin, Caffeine, Diuretics | Mean arterial blood pressure<sup>b</sup> |

<sup>a</sup> Will only include diagnoses in models that were present prior to model specific week during postnatal weeks 1 to 4
<sup>b</sup> Will weight adjust by kg

GA gestational age, BSMSS Barratt Simplified Measure of Social Status, IVH intraventricular hemorrhage
closure in some infants by modifying the effect of determined predictors on PDA-associated outcomes [87], we will evaluate for an interaction when creating prediction models. Persistent ductal patency following prophylaxis may also be a marker of delayed PDA closure. Similar to PDA treatment, the frequency of indomethacin prophylaxis varies between institutions and individual providers [20, 88]. Our retrospective data (10/2012–7/2017) showed that a small minority (15.7%) of clinicians within the NCH Neonatal Network treat infants born ≤29-weeks gestation with indomethacin prophylaxis.

**Prospective collection of PDA indicators in untreated infants**

**Traditional indicators**

The clinical signs associated with PDA shunting depend on shunt magnitude and the compensatory ability of the heart. Table 2 details the patient study timeline.

| Study Period | <72 h | Week 1 | Week 2 | Week 3 | Week 4 | Bi-weekly | 36-weeks PMA | Every 2-3 months | 22 to 26-months CA |
|--------------|-------|--------|--------|--------|--------|-----------|--------------|-----------------|------------------|
| Enrollment   |       |        |        |        |        |           |              |                 |                  |
| Eligibility screen (Echocardiogram) |       |        |        |        |        |           |              |                 |                  |
| Informed consent |       |        |        |        |        |           |              |                 |                  |
| Data collection |       |        |        |        |        |           |              |                 |                  |
| Biomarkers | X | X | X | X | X |           |              |                 |                  |
| Echocardiography * | X | X | X | X | X |           |              |                 |                  |
| Assessments |       |        |        |        |        |           |              |                 |                  |
| Respiratory support |       |        |        |        |        |           |              |                 |                  |
| Echocardiography * | X | X | X | X | X |           |              |                 |                  |
| Bayley III b |       |        |        |        |        |           |              |                 |                  |
| Catheter-based PDA Closure c |       |        |        |        |        |           |              |                 |                  |

* traditional, myocardial deformation imaging, tissue Doppler imaging  
  b Bayley Scales of Infant and Toddler Development, 3rd Edition (Gross Motor Development Scaled Standard Score postnatal age, Fine Motor Development Scaled Standard Score postnatal age, Cognitive Composite Score, Language Composite Score)  
  c patients with persistent PDA at 22 to 26-months corrected age (CA)  
  d obtained bi-weekly until 36-weeks postmenstrual age (PMA) if PDA remains open  
  e all infants receive echocardiogram at 36 weeks irrespective of previous PDA status  
  f until documented ductal closure per local standard of care  

Note: If PDA closed, additional weekly echocardiograms not obtained

---

![Kaplan-Meier Survival Estimates](image)

**Fig. 1** Inpatient Ductal Patency by Gestation over Time. 50% patent ductus arteriosus (PDA) prevalence in preterm infants (n=244): 23-24 weeks (113 d); 25-27 weeks (82 d); 28-29 weeks (30 d). Log-rank test, p=0.0003
immature myocardium to handle the additional volume load [89]. Historically, some NICUs relied solely on clinical examination for PDA diagnosis [90]. While more recently, investigators have challenged the isolated use of clinical signs [90–99], no studies have prospectively evaluated the accuracy and reliability of clinical examination in a large, prospective cohort of <30-weeks gestation infants, or evaluated those findings alongside echocardiographic or biomarker data.

Traditional echocardiography is the gold-standard for PDA diagnosis and provides assessment of ductal diameter, shunting pattern, and volume [100]. Echocardiographic indices can be used to define the hemodynamic significance of PDA. However, because the relative benefits and limitations of PDA echocardiographic indexes remain poorly characterized [100], we will comprehensively examine a multitude of potential parameters. All traditional echocardiograms will assess standard M-mode, two-dimensional, pulsed-wave Doppler, continuous-wave Doppler, and color Doppler evaluations (PDA size [46, 52, 101–104], shunt pattern, shunt volume [55, 100, 105]).

Advanced indicators

**Tissue Doppler imaging** Tissue Doppler imaging can provide quantitative measures of the velocity of myocardial contraction and relaxation throughout the cardiac cycle as a reflection of cardiac performance. Because both systolic and diastolic information are contained in a single tracing, simultaneous isovolemic contraction and relaxation time intervals can be obtained. Tissue Doppler imaging can also be used to calculate a myocardial performance index that reflects both systolic and diastolic global function [106]. In older patients, quantitative assessment of cardiac function with tissue Doppler imaging is a more sensitive indicator of myocardial dysfunction and may provide earlier detection prior to the more qualitative changes observed with traditional echocardiography [107]. While tissue Doppler imaging measurements have been published for both children [108] and fetuses [109], minimal data are available on infants with pathology. Our group was one of the first to show that both collection and interpretation of tissue Doppler imaging are feasible in extremely preterm infants [65].

Tissue Doppler images will be obtained from the apical 4-chamber view with the point of interest along the annulus at the following 3 segments: right ventricle free wall; interventricular septum; and left ventricle free wall. Tissue Doppler imaging tracings will demonstrate a systolic wave, early and late diastolic waves for each segment, and simultaneous isovolemic contraction and relaxation time intervals.

**Myocardial deformation imaging** Myocardial deformation imaging assesses strain (change in myocardium length relative to its resting length, expressed as a percentage) and strain rate (deformation over time) [110–112]. In contrast with traditional echo, but similar to tissue Doppler imaging, myocardial deformation imaging quantitatively assesses myocardial function [63, 113–118]. However, unlike tissue Doppler imaging, myocardial deformation imaging is not influenced by loading conditions (preload or afterload), which may be highly variable in premature infants, particularly those requiring intensive care [65, 119].

Right and left ventricle myocardial deformation imaging strain will be assessed using two-dimensional, apical 4-chamber images [110, 113]. The myocardial walls will be divided into 6 segments. Strain curves will be traced from the basal lateral atrioventricular valve annulus to apex to basal interventricular septum for both right and left ventricles. Strain curves will only be accepted after visual inspection of tracing with manual adjustment of range of interest. If tracing is not adequate in all 6 segments per visual inspection and the software, the image will not be used [63].

**Biomarkers** If either the clinical exam or biomarkers can replace the more costly and labor-intensive echocardiographic techniques at specific postnatal time-points in some predictive models (each echocardiogram is >10-times the cost of the proposed biomarker tests), health care costs would be greatly reduced [120]. Interest in biomarkers to diagnose, stage, and predict hemodynamic and cardiovascular disease in adults and children continues to increase [100, 121–123]. However, no studies have determined, in a large prospective cohort of extremely low birth weight infants, the accuracy and reliability of serum and urinary biomarkers to predict PDA duration and associated outcomes, nor have those findings been evaluated alongside clinical and echocardiographic data. The selected biomarkers appear un-influenced by gestational age, birth weight, and antenatal and postnatal events, making them ideal for evaluating PDA-related myocardial damage and hemodynamic status in preterm infants [120, 124–136].

Weekly blood and urine samples for biomarker analysis will be collected within one calendar day of the echocardiogram for the first 4 weeks postnatal. Blood draws (0.5 mL) will be collected concurrently with weekly nutrition labs that are obtained on all premature infants per local standard of care. Blood samples will be capillary (always concomitant with scheduled clinical blood draws) or arterial if a pre-existing indwelling line is present. Cotton balls will be put in the diapers of enrolled infants to collect urine. De-identified and labeled blood and urine samples will be transported on ice to
the Center for Perinatal Research at NCH where samples will be centrifuged, and frozen in a dedicated freezer at \(-70^\circ\)C for batch analysis. We have locally validated the serum and urine biomarkers for our specific patient population.

**Serum biomarkers** To avoid excessive blood collection in preterm infants two serum natriuretic peptide biomarkers were selected a priori: beta-natriuretic peptide and N-terminal pro-B-type natriuretic peptide, which have been shown to predict likelihood of spontaneous PDA closure, respiratory outcomes, mortality, and neurodevelopment [124–129, 131, 137–140]. Both are cardiac hormones that rapidly respond to volume and pressure overload and are elevated in patients with left and right heart failure. Concentrations of both peptides directly correlate with severity of ductal shunting [133, 134]; levels decrease with successful ductal closure [120, 125, 131, 141]. Brain natriuretic peptide is significantly related to shunt magnitude at the time of measurement, and has good discriminating power for detecting moderate-to-large PDA shunts [125].

**Urinary biomarkers** Ductal shunting may decrease renal and mesenteric bed perfusion [40, 142, 143]. We will use urine (non-invasive, minimal processing) to evaluate two exploratory biomarkers of end-organ ischemia. Neutrophil gelatinase-associated lipocalin is a well-described diagnostic marker of acute renal failure [144–147] with high sensitivity and specificity [148–152]. Heart-type fatty acid-binding protein is an intracellular lipid-binding protein, and expression is stimulated by lipid metabolism alterations, including ischemia. Increased heart-type fatty acid-binding protein levels suggest mesenteric hypoperfusion [153]. Small pilot studies have shown that urinary measurement of both peptides is feasible in preterm infants and appear promising as tools for quantifying the effect of a PDA on systemic perfusion [15, 154].

**Outcome measures**

**Aim 1**

To estimate the probability of spontaneous PDA closure and predict the timing of ductal closure using echocardiographic, biomarker, and clinical predictors obtained within the first postnatal month.

Until documented PDA closure, echocardiograms will be conducted weekly for the first 4 weeks postnatal and biweekly thereafter, between study entry and 36-weeks PMA on all inpatient study participants. Based on local pilot data, we expect 15% of PDAs (90% small, <1.5 mm; 10% moderate, 1.5-2 mm) to remain patent at NICU discharge. All preterm infants with PDA at discharge will follow-up with the pediatric cardiologist at the dedicated neonatal-cardiology clinic within The Heart Center at NCH (sole pediatric cardiology provider-site for central Ohio). Per local standard of care, these infants will receive echocardiograms at 2-3 month intervals until documented closure; any infants with a persistent PDA at 22 to 26-months postnatal age (~5% of those discharged with a persistent ductus) will undergo catheter-based closure to prevent long-term complications of PDA (Table 2) [48, 49]. This will facilitate precise documentation of ductal patency duration from 72-hours postnatal until neurodevelopmental follow-up at 22 to 26-months. We will model clinical measures, weekly biomarker measurements, and weekly echocardiography-derived predictors (as described above) from the first 4 postnatal weeks, when the decision to initiate pharmacologic treatment closure for PDA is most commonly made [18]. The primary outcome for Aim 1 is documented PDA closure by 36-weeks PMA.

**Expected Outcomes** A combination of echocardiographic measures, biomarkers, illness severity, and patient demographics is expected to accurately predict in the first postnatal month, both the probability of an infant’s PDA closing and the duration of PDA patency. Developing a clinically useful prediction model will allow clinicians and clinical trialists to estimate the probability of an infant’s PDA closing and the chronological age at which closure will likely occur.

**Aim 2**

To determine in preterm infants with PDA within the first postnatal month which echocardiographic predictors and biomarkers are predictive of mortality and severity of respiratory illness at 36-weeks postmenstrual age.

After controlling for respiratory severity and other clinical severity of illness markers (Table 1), we will incorporate longitudinally-measured echocardiographic and biomarker variables from the first 4-weeks postnatal to estimate the specific contribution of PDA to mortality or the need for supplemental respiratory support (oxygen or positive-pressure ventilation) at 36-weeks PMA (primary outcome) (Table 3). Such composite primary outcomes are standard in neonatal clinical trials due to competing risks between mortality and other important neonatal outcomes [155, 156].

An infant’s daily respiratory support modality record at 36-weeks PMA closely correlates with important long-term respiratory and neurodevelopmental outcomes [84, 157]. CLD severity at 36-weeks PMA is the neonatal CLD outcome marker most commonly used in randomized trials [155, 158]. Per the National Institutes of Health Consensus Definition, respiratory support via supplemental oxygen at 36-weeks PMA defines moderate CLD (BPD), whereas invasive or noninvasive ventilation
(i.e., continuous positive airway pressure) defines severe CLD (BPD). Infants in the NCH Neonatal Network are never discharged to home prior to 36-weeks PMA unless weaned from all respiratory support including supplemental oxygen (i.e., negative CLD outcome). For those infants transferred before 36-weeks PMA, we will maintain contact with the receiving NICU. In the unlikely case that a transferred infant is lost to follow-up, we will adapt the method of imputing CLD at the time of transfer used by the NICHD NRN to create a validated BPD prediction tool [46, 81].

**Expected Outcomes** We expect to accurately predict the probability of mortality or requirement for supplemental oxygen or positive pressure support at 36-weeks PMA using a combination of echocardiographic measures, biomarkers, and clinical measures from the first 4-weeks postnatal. We will develop a clinically useful prediction model that will allow clinicians and those conducting clinical trials to estimate by week in the first 4 postnatal weeks, the probability of mortality or moderate/severe CLD (BPD) development. We will also evaluate the impact of spontaneous PDA closure and duration of PDA exposure on the 36-weeks PMA outcomes. Early prediction of PDA-associated complications will be crucial to future trial development to determine the population of infants who may require interventional PDA treatment and the ideal timing for such an intervention.

**Aim 3** To determine which echocardiographic predictors and biomarkers in preterm infants with PDA within the first postnatal month are associated with 22 to 26-month neurodevelopmental outcomes.

The extent to which PDA persistence and/or severity contribute to childhood neurodevelopmental impairment is not fully known. The high-risk subset of children who undergo surgical PDA ligation also have the highest probability of neurodevelopmental impairment. Prior to ligation, they have altered cerebral perfusion [11, 159, 160] and long-term decreased cerebral oxygen with associated lower cerebral volumes at term adjusted age relative to infants with earlier PDA closure [11]. For most of the last decade, surgical ligation itself was thought to contribute to worse outcomes [161, 162]. However, a recently published study showed that underlying exposure to severe PDA is a likely cause of worse outcomes [163].

We will incorporate longitudinally-measured echocardiographic and serum biomarker variables from the first 4-weeks postnatal to estimate the specific contribution of PDA to composite motor score (*primary outcome*) and gross motor, fine motor, cognitive composite, and language composite scores (*secondary outcomes*) at 22 to 26-months corrected age (age since birth–number of weeks born before 40-weeks gestation) (Table 4) as measured by the Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley III) [164]. The Barratt

### Table 3 Aim 2 Outcome Measures and Mediators at 36-weeks postmenstrual age

| Primary Outcome | Secondary Outcomes | Covariates of Interest |
|-----------------|--------------------|------------------------|
| Mortality or supplemental oxygen or positive pressure respiratory support at 36-weeks postmenstrual age (binary) | Mortality (binary) | Spontaneous PDA closure (binary) |
|                 | Time to full enteral feeds (binary) | PDA Duration (continuous) |
|                 | Oral feeding status (binary) | |
|                 | Oxygen Dependency (Moderate BPD) (binary) | |
|                 | Positive-Pressure Dependency (Severe BPD) (binary) | |

**Table 4** Aim 3 Outcome Measures at 22 to 26-months corrected age

| Primary Outcome | Secondary and Exploratory Outcomes | Covariates of Interest |
|-----------------|------------------------------------|------------------------|
| Composite Bayley III Motor Score (continuous) | Secondary | Spontaneous PDA closure (binary) |
|                 | Bayley III Gross Motor Development Scaled Standard | PDA Duration (continuous) |
|                 | Score postnatal age (continuous) | Oxygen Dependency at 36-weeks postmenstrual age (binary) |
|                 | Bayley III Fine Motor Development Scaled Standard | |
|                 | Score postnatal age (continuous) | |
|                 | Bayley III Cognitive Composite Score (continuous) | |
|                 | Bayley III Language Composite Score (continuous) | |
|                 | Exploratory | |
|                 | Supplemental oxygen support (binary) | |
|                 | Supplemental positive-pressure ventilation support (binary) | |
|                 | Growth (weight, height, Body Mass Index) (binary) | |
|                 | Feeding (full oral feeding, gastric-tube) (binary) | |
Simplified Measure of Social Status [165] will be administered to all mothers at study consent to allow adjustment for the influence of socioeconomic status and education within the home environment. Our focus will be on combined motor outcomes at 22 to 26-months because postnatal motor outcomes are nearly unaffected by post-discharge socioeconomic influences [166]. In addition, motor outcomes are a good surrogate for disease-induced global neurologic impairment, because these are largely explained by various degrees of brain injury, whether identified by neuroimaging, or occult and inferred from documented accumulated inflammatory and oxidative stress exposures [167–169].

The Bayley III [164] is validated for 22 to 26-months corrected age neurodevelopmental measurement in extremely preterm neonates and is the gold-standard for the evaluation of former NICU graduates [170]. Bayley III scores are normed against a large population and designed to be adjusted for prematurity. Neurodevelopmental measurement at 22 to 26-months is standard for major neonatal trial groups including the NICHD NRN [171]. We have demonstrated our ability, as a NICHD NRN study center since 2011, to accurately and prospectively collect 36-week BPD severity data and 2-year neurodevelopmental assessments including Bayley III scores for infants born at 22 to 27-weeks gestational age and/or birth weight <1000 grams in our follow-up programs [172, 173]. The Bayley III is administered in the NCH Neonatal Follow-Up Program by trained examiners who undergo yearly retraining and certification by NRN gold-standards with research follow-up rates at 22 to 26-months exceeding 90%.

Research personnel will work with families to schedule visits at times that best meet family needs. Loss to follow-up will be minimized by rescheduling the Bayley III should a child not be able to complete testing during the originally scheduled time. If necessary, experienced testers will perform the Bayley III in the home environment, as successfully implemented in local NRN studies. All examiners will be masked to randomization group.

We will develop prediction models that will estimate an infant’s probability of motor delays at 22 to 26-months (primary outcome). In addition, we will examine the effect of PDA duration as a specific feature of 22 to 26-month neurodevelopmental impairment to more thoroughly evaluate the contribution of extended PDA exposure to these outcomes (Table 4).

**Expected Outcomes** A combination of echocardiographic measures, biomarkers, and clinical measures collected in the first postnatal month is expected to accurately predict the probability of PDA-associated motor impairment at 22 to 26-months corrected age. A clinically useful prediction model will allow clinicians and those performing clinical trials to estimate, per week within the first postnatal month, the probability of PDA-associated neurodevelopmental impairment at 22 to 26-months corrected age. We will also evaluate the impact of spontaneous PDA closure and duration of PDA exposure on motor outcomes at 22 to 26-months.

**Development of Online Clinical Prediction Tool**

**PDA treatment parameters and frequencies** vary markedly between institutions and individual care providers [17–20]. Over the past decade, the American Academy of Pediatrics [3] has increasingly advocated for a validated PDA-severity grading-system to permit selective treatment of preterm infants with PDA who are most likely to benefit. We will use our final, validated models to create a web-based tool that predicts an infant’s unique probability of spontaneous PDA closure, mortality or 36-weeks PMA respiratory support requirement, and 2-year neurodevelopmental impairment.

**Statistical analyses**

**Aim 1: Statistical Methods**

Recognizing that some babies may die prior to PDA closure, models considered will accommodate the competing risk of death prior to closure through a subdistribution hazards model of Fine and Gray [174, 175]. In development of a model to establish a rigorous prediction of PDA closure risk, a penalized variable selection method developed for the Fine and Gray framework will be considered in the model development stage (detailed below) [176]. As a comparison to these models, not accounting for the potential of competing risks will be explored using the Cox model framework. If catheter-based closure is performed (<3% of infants within our regional network), we will censor the observed follow-up time at the time of last recorded PDA, and model the impact of recorded duration of PDA exposure (in postnatal weeks).

**Model development/training stage** A multivariable prediction model for PDA closure risk will be developed in the training cohort (n=450) based on verified features identified by previous work and our hypothesized new covariates of interest (echocardiographic and serum biomarker measures and magnitude of respiratory support in the first 4-weeks postnatal). The test/validation set that will be recruited in the year following the initial cohort is expected to consist of 225 neonates. Hierarchical clustering will be used to display the unique patterns of PDA closure based on the top echocardiographic, biomarker, demographic, and clinical features. We hypothesize that in addition to echocardiographic and serum biomarker measures, the magnitude of respiratory support in the first 4-weeks postnatal is an important
predictor of PDA closure. Higher respiratory support may predict delayed closure and modify the effect of echocardiographic and serum biomarker measures of PDA intensity on closure probability. Therefore, we will examine interactions between respiratory measures (treatment modality, mean daily FiO₂, and mean oxygen saturation index on the day of the weekly echo) and PDA, in addition to individual features.

A ten-fold cross validation procedure will be iterated 500 times to develop the optimal diagnostic model. In each cross validation iteration, the full training cohort will be randomly split into ten equal partitions. Each fold will take turns to be the test set and the other nine to be the training set. For each fold, a penalized Fine and Gray model regression (e.g., LASSO or SCAD) will be used to select the top predictors of PDA closure risk. The “inner-run” cross-validation and area under the receiver operating curve (AUC) will be used to choose the optimal tuning parameter. Based on the optimal tuning parameter, the selected model prediction accuracy and sensitivity/specificity will be evaluated based on the test set. An overall receiver operating curve and AUC based on all test set samples will be plotted and estimated after running all 10 folds. The aforementioned cross validation procedure will be replicated 500 times and the distribution of the overall model performance (AUC, specificity, sensitivity) will be obtained. If the average AUC is acceptable (≥0.70) and the variance is limited (0.05), the final model will be estimated with the entire test set.

Model validation stage The final predictive model formulated at the training stage will be validated in an independent validation, derived from approximately 225 participants in the cohort recruited the year following enrollment of the initial training cohort. Model prediction accuracy will be evaluated by AUC, with an AUC performance ≥0.70 of interest for further exploration in larger cohorts.

Aim 2: Statistical Modeling and Methods
As in Aim 1, we will focus on building predictive models. For the composite outcome of mortality or supplemental oxygen or positive-pressure respiratory support at 36-weeks PMA, we will adopt the same structure as in Aim 1, by utilizing the training (450 patients) and validation cohort, recruited thereafter.

Together with clinical features that include respiratory severity and other markers of clinical severity of illness (Table 1), longitudinally-measured echocardiographic and biomarker variables from the first 4-weeks postnatal will be incorporated to predict the composite endpoint of mortality or need for oxygen or positive-pressure support at 36-weeks PMA (primary outcome) or mortality (secondary outcome). A ten-fold cross validation procedure will be iterated 500 times to develop the optimal diagnostic model. Penalized logistic regression (SCAD, MCP, LASSO) will be utilized to predict our composite outcome and select the top predictors of mortality and CLD risk. We will choose the optimal tuning parameter, determine prediction accuracy and sensitivity/specificity, and estimate the final model with the entire test set as described above.

Given our interest in both the impact of PDA duration and the additional benefit of PDA closure on outcomes (in addition to echo and biomarker predictors over clinical risk factors alone), we will force these two measures (PDA duration and closure) into the model and subsequently compare model fit and accuracy to the models of best predictors that exclude them. Furthermore, we will explore interactions/effect modification between respiratory and other risk factors and PDA measurements (echocardiographic, biomarker) to predict outcomes. Final models (one each for primary and secondary outcomes) will be fit to the validation cohort, and the model fit summarized as previously detailed.

Aim 3: Statistical Analysis
To predict longer-term neurodevelopment outcomes, we will follow the methods described above, utilizing cross validation together with penalized regression models using re-sampling to evaluate the best model choice and to facilitate model building on the training set. As detailed above, we will force PDA measures into our models and evaluate these against models without these measures. For continuous outcomes we will examine the mean square error and Akaike information criterion. Final models for each outcome will be fit and evaluated in the validation cohort. Although we do not expect a large number of patients to be lost to follow-up or to die during follow-up (~10%), we will also explore models that will jointly model neurodevelopment outcomes and time to loss or death with a Cox survival model. We will follow the same general framework for model development as previously described, using a joint random-intercept Cox model [177].

Sample size and power
Sample size in the training/model building stage is based on the justification according to Dobbin et al. [178] and Pang et al. [179] Given that we expect the majority of PDA closures by 36-weeks PMA (Aim 1) following enrollment (upwards of 80-85% of the 450 in the training stage), and the relatively limited set of potential covariates, we expect our resulting classification from the training set to have a tolerance/accuracy of at most 0.05 of the optimal accuracy. An accuracy of 0.05 can be interpreted as the expected accuracy of the classifier to
be within 5% of the "best" possible accuracy achieved with a binary classifier. Moreover, with 10-fold cross validation, we expect that power will be high (over 80%) with two-sided type I error of 5% with the expected 450 patient target accrual and modest hazard ratios between 1.5-2.0.

Assuming approximately ¼ of patients (n=112) will experience the Aim 2 primary outcome event, we expect our resulting classification from the training set to have a tolerance/accuracy of at most 0.05 of the optimal accuracy using the justification according to Dobbin et al. [178, 179]

Missing Data
We do not anticipate missing covariate data since we will prospectively record data. However, should substantial covariate data be missing, we will employ multiple imputation techniques.

Discussion
The strengths of this investigation include a prospective cohort design within a unique population of untreated infants with PDA, and innovative modeling using advanced echocardiography, biomarkers, and clinical measures to accurately predict not only spontaneous PDA closure timing, but which infants with persistent PDA are at the highest risk for worsened PDA-associated outcomes (mortality, CLD, neurodevelopmental impairment). This novel approach will fulfill a critical American Academy of Pediatrics clinical research objective [3] by determining the relative added contribution of echocardiography and biomarkers at specific weekly intervals over measurable clinical risk factors alone. Following optimization of our prediction models using 10-fold cross validation and penalized regression, all prediction models will be independently validated in a second cohort of patients.

The results from this study will immediately inform clinical decision-making and, as a critical step to designing trials that will enroll appropriate participants in randomized trials, will ultimately lead to improved outcomes for preterm infants with PDA. Our weekly prediction models for the first postnatal month, the period of PDA-associated outcomes. Our team has experience in applying composite outcomes and guarding against mortality-associated biases, such as for immortal-time bias, in the preterm infant population [18, 180]. For Aim 2 we will employ a primary mortality or CLD composite outcome at 36-weeks PMA, the accepted practice among neonatal randomized trialists. For Aim 1 (spontaneous closure) outcomes we will employ Fine and Gray subdistribution hazards models, which will allow us to account for competing mortality risks and limit the analysis to observed follow-up time. In Aim 3 (neurodevelopmental outcomes at 22 to 26-months) we will explore using joint models to account for drop out and potential death.

Supplementary information
Supplementary Information accompanies this paper at https://doi.org/10.1186/s12887-019-1708-z.

Abbreviations
AUC: Area under the receiver operating curve; Bayley III: Bayley Scales of Infant Development, 3rd Edition; BPD: Bronchopulmonary dysplasia; CLD: Chronic lung disease; FiO2: Fraction of inspired oxygen; NCH: Nationwide Children’s Hospital; NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development; NICU: Neonatal intensive care unit; NRN: NICHD Neonatal Research Network; PDA: Patent ductus arteriosus; PMA: Postmenstrual age

Acknowledgements
Not applicable

Authors’ contributions
CB, EH, JN, NM, MK, MI, VL, and JS made substantial contributions to the conception and design of the study. CB, CC, JN, BR, LM, MI, VL, and JS made substantial contributions to acquisition of data. EH, VL, and JS conducted the statistical analysis. CB, DL, and JS wrote the manuscript. All authors read and approved the final manuscript.

Funding
Research described in this publication was supported by the National Heart, Lung, and Blood Institute (NHLBI; https://www.nhlbi.nih.gov/) of the National Institutes of Health (United States of America) under Award Number R01HL145032 to JS and CB. The project described was also supported by the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002733. The content is solely the responsibility of the authors and does not necessarily represent the
official views of the National Center For Advancing Translational Sciences or the National Institutes of Health.

Availability of data and materials
Data sharing is generally not applicable to this publication as no datasets outside of the presented pilot data were generated or analysed specifically for this prospective cohort protocol. We will share our deidentified pilot data upon request to the corresponding author (CB) and will welcome the opportunity to share data in the future pending the completion of our investigation. Following the completion and publication of our investigation, all patient identifiers will be removed from the final dataset and we will make the data available to other users under a data sharing agreement. We will ask under the agreement that other users will commit to using the data only for research purposes, that they will not identify individual study subjects, that they will securely store the data electronically using password protection or encryption, that they will delete or destroy the data after the completion of their investigation, and that they will acknowledge the contribution of the funding agency (NIH NHLBI) and our investigative team in collecting the original data. Additional study details are summarized in Additional file 1: Table S1.

Ethics approval and consent to participate
This project has been reviewed by the Nationwide Children’s Hospital Institutional Review Board (IRB@nationwidechildrens.org; reference # IRB18-000684) and was approved (10/15/2018). Protocol modifications will be reviewed and approved by the IRB and updated at ClinicalTrials.gov. Written informed consent was obtained from a parent or guardian for participants under 16 years old (copy of the form available from https://clinicaltrials.gov/ProvidedDocs/10/NCT03782610/ICF_000.pdf) will be obtained for all study participants according to the IRB approved protocol.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Center for Perinatal Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, USA. 2Department of Pediatrics, Nationwide Children’s Hospital, 700 Children’s Way, Columbus, Ohio 43205, USA. 3Division of Epidemiology, College of Public Health, The Ohio State University, Columbus, Ohio, USA. 4The Heart Center, Nationwide Children’s Hospital, Columbus, Ohio, USA. 5Division of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, Ohio, USA. 6Department of Obstetrics and Gynecology, College of Medicine, The Ohio State University, Columbus, Ohio, USA.

Received: 25 July 2019 Accepted: 3 September 2019
Published online: 13 September 2019

References
1. Noon S, McCoy M, Friedlich P, Bright B, Gottipati V, Seri I, et al. Failure of duc tus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics. 2009;123(1):e138–e44.
2. Brown ER. Increased risk of bronchopulmonary dysplasia in infants with patent duc tus arteriosus. J Pediatr. 1979;95(5 Pt 2):865–6.
3. Benitz WE. Committee on Fetus and Newborn, American Academy of Pediatrics. Patent Ductus Arteriosus in Preterm Infants. Pediatrics. 2016;137(1):e2015309. https://doi.org/10.1542/peds.2015-3090.
4. Schena F, Francescato G, Cappelleri A, Picciolli I, Mayer A, Mosca F, et al. Patent Ductus Arteriosus and Brain Volume. Pediatrics. 2016;137(4):e20153090. https://doi.org/10.1542/peds.2015-3090.
5. Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? Semin Perinatol. 2012;36(2):123–9.
6. Reese J, Laughon NM. The Patent Ductus Arteriosus Problem: Infants Who Still Need Treatment. J Pediatr. 2015;167(5):S94–6.
7. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the duc tus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics. 2006;117(4):1113–21.
8. Drougia A, Giapros V, Kraliss N, Theocharis P, Nikaki A, Tsoufi M, et al. Incidence and risk factors for cerebral palsy in infants with perinatal problems: a 15-year review. Early Hum Dev. 2007;83(8):541–7.
9. Vincen MJ, Allen AC, Joseph KS, Stinson DA, Scott H, Wood E. Increasing prevalence of cerebral palsy among very preterm infants: a population-based study. Pediatrics. 2006;118(6):1621–6.
10. Padilla N, Alexandre G, Benvin M, Lagescrintz H, Aeden U. Brain Growth, Gains and Losses in Extremely Preterm Infants at Term. Cereb Cortex. 2015;25(7):1897–905.
11. Lemmers PM, Benders MJ, D’Ascerco R, Zethol J, Alderliesten T, Kersbergen KJ, et al. Patent Ductus Arteriosus and Brain Volume. Pediatrics. 2016;137(4):e20153090. https://doi.org/10.1542/peds.2015-3090.
12. Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? Semin Perinatol. 2012;36(2):123–9.
13. Reese J, Laughon NM. The Patent Ductus Arteriosus Problem: Infants Who Still Need Treatment. J Pediatr. 2015;167(5):S94–6.
14. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the duc tus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics. 2006;117(4):1113–21.
15. Tosse V, Pillekamp F, Verde P, Hadzik B, Sabir H, Mayatepek E, et al. Urinary NT-proBNP, NGAL, and H-FABP may predict hemodynamic relevance of patent ductus arteriosus in very low birth weight infants. Neonatology. 2012;101(4):260–6.
16. Benitz WE. Patent ductus arteriosus: to treat or not to treat? Arch Dis Child Fetal Neonatal Ed. 2012;97(2):F78–9.
17. Hagadorn JI, Brownell EA, Trzaski JM, Johnson KR, Lainwala S, Campbell BT, et al. Trends and variation in management and outcomes of very low-birth-weight infants with patent ductus arteriosus. Pediatr Res. 2016;80(5):785–92.
18. Slaughter JL, Reagan PB, Newman TB, Klebanoff MA. Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants. JAMA Pediatr. 2017;171(7):e164354. https://doi.org/10.1001/jamapediatrics.2016.4354.
19. Bixler GM, Powers GC, Clark RH, Walker MW, Tolla VN. Changes in the Diagnosis and Management of Patent Ductus Arteriosus from 2006 to 2015 in United States Neonatal Intensive Care Units. J Pediatr. 2017;189:105–12.
20. Slaughter JL, Reagan PB, Bapat RV, Newman TB, Klebanoff MA. Nonsteroidal anti-inflammatory administration and patent ductus arteriosus litigation, a survey of practice preferences at US children’s hospitals. Eur J Pediatr. 2016;175(6):775–83. https://doi.org/10.1007/s00431-016-2705-y.
21. Cooke L, Steer PA, Woodgate PG. Indomethacin for asymptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2003;2:CD003745.
22. Ohlsson A, Wala R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2015;2:CD003481.
23. Mirea L, Sankaran K, Seshia M, Ohlsson A, Allen AC, Aziz K, et al. Canadian Neonatal Network. Treatment of patent ductus arteriosus and neonatal mortality/morbidity: adjustment for treatment selection bias. J Pediatr. 2012;161(4):689–94. https://doi.org/10.1016/j.jpeds.2012.05.007.
24. Romagnoli C, Bersani I, Rubortone SA, Lacerenza S, De Carolis MP. Current evidence on the safety profile of NSAIDs for the treatment of PDA. J Matern Fetal Neonatal Med. 2011;24(3):10–3.
25. Svanandan S, Bali V, Saraihah AS, Harabor A, Kamaluddeen M. Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants. Am J Perinatol. 2013;30(9):745–50.
26. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli FF. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosis. J Pediatr. 1999;135(6):733–8.
27. Patel J, Roberts I, Azopardi D, Hayden J, Edwards AG. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res. 2000;47(1):36–42.
28. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran S, et al. Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. New Engl J Med. 2001;344(9):95–101.
29. Attridge JT, Clark R, Walker MW, Gordon PV. New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure. J Perinatol. 2006;26(2):293–9.
30. Paquette L, Friedlich P, Ramanathan R, Seri I. Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous...
intestinal perforation in very low birth weight neonates. J Perinatol. 2006;26(8):486–92.
31. Hammerman C, Bin-Nun A, Kaplan M. Managing the patent ductus arteriosus in the premature neonate: a new look at what we thought we knew. Semin Perinatol. 2012;36(2):130–8.
32. Jobe AH. Drug pricing in pediatrics: the egregious example of indomethacin. Pediatrics. 2007;119(6):1197–8.
33. Poon G. Ibuprofen lysine (NeoProfen) for the treatment of patent ductus arteriosus. Proc (Bayl Univ Med Cent). 2007;20(1):83.
34. Ohlsson A, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low-birth-weight infants. Cochrane Database Syst Rev. 2015;3:CDB010061.
35. van den Anker JN, Allegaert K. Acetaminophen to Prevent Symptomatic Patent Ductus Arteriosus: Another Drug Bites the Dust? J Pediatr. 2016;177:7–9.
36. Jevtovic-Todorovic V. Functional implications of an early exposure to cardiorespiratory instability after patent ductus arteriosus ligation. J Am Soc Echocardiogr. 2012;25(10):1058–67.
37. Jevtovic-Todorovic V. Functional implications of an early exposure to spasticity after patent ductus arteriosus ligation: a tissue Doppler and myocardial deformation study. J Am Soc Echocardiogr. 2012;25(10):1058–67.
38. Backes CH, Cheatham SL, Deyo GM, Leopold S, Ball MK, Smith CV, et al. Patent Ductus Arteriosus Occlusion during Cardiac Catheterization in 269 Term Infants: Feasibility and Complications. J Am Heart Assoc. 2016;5(2):e002923. https://doi.org/10.1161/JAHA.115.002923.
39. Backes CH, Kennedy KF, Locke M, Cua CL, Ball MK, Fick TA, et al. Transectorath Occlusion of the Patent Ductus Arteriosus in <747 Infants <6 kg: Insights From the NCDRI IMPACT Registry. JACC Cardiovasc Interv. 2017;10(17):1729–70.
40. Backes CH, Rivera BK, Creutzer J, Armby L, El-Said H, Moore JW, et al. Low weight as an independent risk factor for adverse events during cardiac catheterization of infants. Catheter Cardiovasc Interv. 2013;82(5):786–94.
41. Hamrick SE, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics. 2010;125(5):1020–30.
42. Cynman R. Mechanisms regulating the ductus arteriosus. Biol Neonate. 2006;89(4):330–5.
43. Schneider DJ, Moore JW. Patent ductus arteriosus. Circulation. 2006;114(17):1873–82.
44. Schneider DJ. The patent ductus arteriosus in term infants, children, and adults. Semin Perinatol. 2012;36(2):146–53.
45. Brooks JM, Travadi JN, Patole SK, Doherty DA, Simmer K. Is surgical ligation of the patent ductus arteriosus necessary? The Western Australian experience of conservative management. Arch Dis Child Fetal Neonatal Ed. 2005;90(3):F225–9.
46. Weiss DE, Mirea L, Resende MFM, Ly L, Church PT, Kelly E, et al. Outcomes of Surgical Ligation after Unsuccessful Pharmacotherapy for Patent Ductus Arteriosus in Neonates Born Extremely Preterm. J Pediatr. 2018;195(4):5.
47. McNamara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed. 2007;92(6):F424–7.
48. Sehgal A, Weiss DE, McNamara PJ. Reflections of the changes in patent ductus arteriosus management during the last 10 years. Arch Dis Child Fetal Neonatal Ed. 2016;101(5):F474–8.
49. Sembrovic J, Siric J, Miletin J, Kucerja J, Berka I, Sekbova S, et al. Spontaneous Closure of Patent Ductus Arteriosus in Infants <1500 g. Pediatrics. 2017;140(2):e20164258. https://doi.org/10.1542/peds.2016-4258.
management: the art of medicine remains long. Circulation. 2013;127(4):509–16 discussion 516.

121. Januzzi JL, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. Circulation. 2013;127(4):500–7 discussion 508.

122. Meams BM. Prevention: BNP screening and collaborative care can help to prevent heart failure. Nat Rev Cardiol. 2013;10(9):489.

123. Attridge JT, Kaufman DA, Lim DS. B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed. 2009;59(4):S78–82.

124. Chen S, Tacy T, Clyman R. How useful are B-type natriuretic peptide measurements for monitoring changes in patent ductus arteriosus shunt magnitude? J Perinatol. 2010;30(12):780–5.

125. Hummertman C, Shchors I, Schimmel MS, Bromrik R, Kaplan M, Nir A. N-terminal-pro-B-type natriuretic peptide in premature patent ductus arteriosus: a physiologic biomarker, but is it a clinical tool? Pediatr Cardiol. 2010;31(1):662–5.

126. Hsu JH, Yang SN, Chen HL, Tseng HI, Dai ZK, Wu JR. B-type natriuretic peptide predicts responses to indomethacin in premature neonates with patent ductus arteriosus. J Pediatr. 2010;157(1):79–84.

127. Jeong HA, Shin JH, Kim E, Lee EH, Choi BM, Son CS, et al. Correlation of B-type natriuretic peptide levels and echocardiographic parameters in preterm infants with patent ductus arteriosus. Korean J Pediatr. 2016;59(4):183–9.

128. Kim JS, Shim EJ. B-type natriuretic Peptide assay for the diagnosis and prognosis of patent ductus arteriosus in very preterm infants. J Perinatol. 2005;25(11):709–13.

129. Lee JH, Shin JH, Park KH, Rhee YJ, Park MS, Choi BM. Can early B-type natriuretic peptide assays predict symptomatic patent ductus arteriosus in extremely low birth weight infants? Neonatology. 2013;103(2):118–22.

130. Martinovic D, VanDen Eijnden S, Unger P, Najem B, Gulbis B, Marechal Y. Early NT-proBNP is able to predict spontaneous closure of patent ductus arteriosus in preterm neonates, but not the need of its treatment. Pediatr Cardiol. 2011;32(7):953–7.

131. Sanjev S, Petterson M, Lua J, Thomas R, Shankaran S, L’Ecuyer T. Role of biomarkers in the management of Patent Ductus Arteriosus Ligation With Death or Neurodevelopmental impairment in subjects affected by chronic kidney disease. Kidney Blood Press Res. 2008;31(4):274–9.

132. Weisz DE, McNamara PJ, El-Khuffash A. Cardiac biomarkers and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. Kidney Blood Press Res. 2008;31(4):277–8.

133. Bolignano D, Mine K, Ohashi A, Tsuji S, Nakashima J, Hirabayashi M, Kaneko K. B-type natriuretic Peptide assay for the diagnosis and prognosis of patent ductus arteriosus. J Perinatol. 2011;31(3):150–6.

134. Bolignano D, Lacquaniti A, Campo S, Buemi A, Nicocia G, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis. 2008;52(3):595–605.

135. Bolignano D, Lacquaniti A, Coppolino G, Campo S, Buemi A, Lacquaniti A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press Res. 2008;31(4):255–8.

136. Cooper DS, Sharple JR, Flores FX, William Gaynor J, Salvin JW, Devrajan P, et al. Acute kidney injury and critical cardiac disease. World J Pediatr Congenit Heart Surg. 2011;2(3):411–23.

137. Haase M, Devrajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011;57(17):1752–61.

138. Krawczeski CD, Goldstein SL, Woo JG, Wang Y, Piapayanghe N, Ma Q, et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol. 2011;58(22):2301–9.

139. Krawczeski CD, Woo JG, Wang Y, Bennett MR, Ma Q, Devrajan P. Neutrophil gelatinase-associated lipocalin concentrations predict development of acute kidney injury in neonates and children after cardiopulmonary bypass. J Pediatr. 2011;158(6):1009–15.e1.

140. Parikh CR, Coca SG, Thiessen-Philbrook H, Shlipak MG, Koyner JL, Wang Z, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol. 2011;22(9):1748–57.

141. Pelsers MM, Hermens WT, Glatz F. Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta. 2005;352(2-3):215–35.

142. Laverty AJ, Meinen-Derr JK, Anderson E, Ma Q, Bennett MR, Devrajan P, et al. Urinary NGAL in premature infants. Pediatr Res. 2008;64(4):423–8.

143. Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, et al. Early CPAP versus surfactant in extremely preterm infants. New Engl J Med. 2010;362(21):1970–9.

144. Kirpalani H, Milic D, Lemnyre B, Yoder BA, Chiu A, Roberts RS, et al. A trial comparing noninvasive ventilation strategies in preterm infants. New Engl J Med. 2013;369(7):611–20.

145. Ehrenkranz RA, Walsh MC, Vorh BR, Jobe AH, Wright LL, Fanaroff AA, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116(6):1353–60.

146. Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, Carlin JB. Nasal CPAP and intubation at birth for very preterm infants. Pediatrics. 2005;116(6):e1353–60.

147. Perlman JM, Hill A, Volpe JJ. The effect of patent ductus arteriosus on flow in the systemic arteries and physiological significance of a patent ductus arteriosus. J Pediatr. 2008;153(1):e6–7.

148. Leite SR, Cunha AC, de Jesus GP, de Godoy MP, de de Carvalho MS, et al. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterm. J Pediatr. 2007;150(3):229–34.e1.

149. Lee GR, Sohn YB, Kim MJ, Jeon GW, Shiv JW, Chang YS, et al. Outcome following surgical closure of patent ductus arteriosus in very low birth weight infants in neonatal intensive care unit. Yonsei Med J. 2008;49(2):265–71.

150. Weisz DE, Mirea L, Rosenberg E, Jiang M, Ly L, Church PT, et al. Association of Patent Ductus Arteriosus Ligation With Death or Neurodevelopmental Impairment Among Extremely Preterm Infants. JAMA Pediatr. 2017;171(5):7.

151. Albers CA, Greaves BT, Bayley, N.(2006). Bayley scales of infant development third edition. San Antonio, TX: Harcourt assessment. J Psychoeduc Assess. 2007;25(2):180–90.

152. Barratt W. The Barratt Simplified Measure of Social Status (BSMSS): Measuring SES. Unpublished manuscript, 2006. Indiana State University. Available from http://wbarratt.instate.edu/socialall/barratt_simplified_measure_of_social_status.pdf.
166. Singer L, Yamashita T, Lilien L, Collin M, Baley J. A longitudinal study of developmental outcome of infants with bronchopulmonary dysplasia and very low birth weight. Pediatrics. 1997;100(6):987–93.

167. Bennet L, Dhillon S, Lear C, van den Heuij L, King V, Dean JM, et al. Chronic inflammation and impaired development of the preterm brain. J Reprod Immunol. 2017;125:45–55.

168. Picker RH, McGrath JM, Reyna BA, Mc Cain N, Lewis M, Cone S, et al. A model of neurodevelopmental risk and protection for preterm infants. Adv Neonatal Care. 2013;13(Suppl 5):S11–20.

169. Picker RH, McGrath JM, Reyna BA, Mc Cain N, Lewis M, Cone S, et al. A model of neurodevelopmental risk and protection for preterm infants. J Perinat Neonatal Nurs. 2010;24(4):356–65.

170. Pappas A, Adams-Chapman L, Shankaran S, McDonald SA, Stoll BJ, Laptok AR, et al. Neurodevelopmental and Behavioral Outcomes in Extremely Premature Neonates With Ventriculomegaly in the Absence of Periventricular-Intraventricular Hemorrhage. JAMA Pediatr. 2018;172(1):32–42.

171. Boghossian NS, McDonald SA, Bell EF, Carlo WA, Brumbaugh JE, Stoll BJ, et al. Association of Antenatal Corticosteroids With Mortality, Morbidity, and Neurodevelopmental Outcomes in Extremely Preterm Multiple Gestation Infants. JAMA Pediatr. 2016;170(6):593–601.

172. Maitre NL, Smolinsky C, Slaughter JC, Stark AR. Adverse neurodevelopmental outcomes after exposure to phenobarbital and levetiracetam for the treatment of neonatal seizures. J Perinatol. 2013;33(11):841–6.

173. Maitre NL, Marshall DD, Price WA, Slaughter JC, O’Shea TM, Maxfield C, et al. Neurodevelopmental outcome of infants with unilateral or bilateral periventricular hemorrhagic infarction. Pediatrics. 2009;124(6):e1153–60.

174. Austin PC, Lee DS, D’Agostino RB, Fine JP. Developing points-based risk-scoring systems in the presence of competing risks. Stat Med. 2016;35(22):4056–72.

175. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.

176. Fu Z, Parkh CR, Zhou B. Penalized variable selection in competing risks regression. Lifetime Data Anal. 2017;23(3):353–76.

177. Henderson R, Diggle P, Dobson A. Joint modelling of longitudinal measurements and event time data. Biostatistics. 2000;1(4):465–80.

178. Slaughter JL, Klebanoff MA. Neurodevelopmental Outcome in Relation to Treatment of Patent Ductus Arteriosus. JAMA Pediatr. 2017;171(10):1017–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.